Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner

Megan E. Bosch,Hemraj B. Dodiya,Julia Michalkiewicz,Choonghee Lee,Shabana M. Shaik,Ian Q. Weigle,Can Zhang,Jack Osborn,Aishwarya Nambiar,Priyam Patel,Samira Parhizkar,Xiaoqiong Zhang,Marie L. Laury,Prasenjit Mondal,Ashley Gomm,Matthew John Schipma,Dania Mallah,Oleg Butovsky,Eugene B. Chang,Rudolph E. Tanzi,Jack A. Gilbert,David M. Holtzman,Sangram S. Sisodia,Matthew John Schipma…

DOI: https://doi.org/10.1186/s13024-023-00700-w

2024-02-19

Molecular Neurodegeneration

Abstract:It has recently become well-established that there is a connection between Alzheimer's disease pathology and gut microbiome dysbiosis. We have previously demonstrated that antibiotic-mediated gut microbiota perturbations lead to attenuation of Aβ deposition, phosphorylated tau accumulation, and disease-associated glial cell phenotypes in a sex-dependent manner. In this regard, we were intrigued by the finding that a marine-derived oligosaccharide, GV-971, was reported to alter gut microbiota and reduce Aβ amyloidosis in the 5XFAD mouse model that were treated at a point when Aβ burden was near plateau levels. Utilizing comparable methodologies, but with distinct technical and temporal features, we now report on the impact of GV-971 on gut microbiota, Aβ amyloidosis and microglial phenotypes in the APPPS1-21 model, studies performed at the University of Chicago, and independently in the 5X FAD model, studies performed at Washington University, St. Louis.

neurosciences

What problem does this paper attempt to address?

The problem this paper attempts to address is the exploration of the effects of a marine-derived oligosaccharide called sodium oligomannate (GV-971) on Alzheimer's disease (AD) pathology. Specifically, the study aims to verify and extend previous findings on whether GV-971 can improve Alzheimer's disease symptoms by altering the gut microbiota, reducing amyloid plaque deposition in the brain, and modulating neuroinflammation, and whether these effects are gender-specific.

The main objectives of the paper include:
1. **Verify the efficacy of GV-971**: Test the effects of GV-971 in two different transgenic mouse models (APPPS1-21 and 5XFAD).
2. **Explore gender differences**: Investigate whether the effects of GV-971 differ between male and female mice.
3. **Analyze microbiome changes**: Assess the impact of GV-971 on the gut microbiome and its relationship to brain pathology.
4. **Explore neuroinflammation mechanisms**: Study how GV-971 affects the activation state of microglia and astrocytes.

Overall, the study aims to reveal the potential mechanisms of GV-971 in treating Alzheimer's disease and further understand its effects on the microbiome-microglia-amyloid axis.